

Commentary

With the news and uncertainty that followed the new COVID-19 variant, Omicron, global assets went into risk-off mode with USD strong against many currencies including AUD (+5.5%). Against this backdrop, global equities were weak in November (-2.4% in USD, but +3.4% in AUD following the strength in the USD) with Information Technology, Consumer Discretionary and Utilities outperforming, whilst Energy, Financials and Communication Services underperformed.

US equities outperformed in a relative sense (+4.8%) with US Federal Reserve (Fed) policy on track, Fed chair Powell staying on for another term and President Biden's Build Back Better \$1.7t bill gaining political traction. European equities were weak (+0.5%) with some countries announcing the reintroduction of COVID-19 restrictions due to surging rates in the COVID-19 Delta variant.

Asian equities underperformed (+2.4%) with Chinese equities weak (+2.0%) amidst continued regulatory headlines and speculation of the delisting of variable interest entities (VIE). Japan was inline (+3.3%) with growth evident in the macro data.

Elsewhere, Brent Crude (-16.4% in USD) tumbled with Omicron variant fears, while Gold (-0.5%) was slightly down and the US Dollar (DXY +2%) overall was strong.

Key contributors included:

- Hardware cluster, notably Mediatek and Seagate Technology. Mediatek reacted positively after the unveiling of its latest flagship chip, the Dimensity 9000 which is poised to rival competitor high-end chips in powering premium mobile devices. Seagate Technology continued a strong post-earnings run after exceeding analyst expectations for

revenue, earnings and December quarter guidance, fuelled by the unveiling of new technology that integrates hard disk drives with non-volatile memory express (NVMe) protocol, previously only compatible with solid state drives.

- Frontier Communications, within the Infrastructure/Property Developed Markets cluster reacted positively on the back of US Congress passing a US\$1.7t infrastructure bill which included a total of \$US65m dedicated for broadband deployment.
- Internet/Software - Developed Markets cluster, notably Amazon and Microsoft, benefitting from a flight to quality growth stocks over the month.

Key detractors included:

- Healthcare cluster, notably Merck and Philips. Merck reacted to news in November whereby it was reported that its oral Covid antiviral drug reduced the risk of patients developing severe cases or requiring hospitalisation by 30%, which was lower than the previously stated 50% reduction. Philips reacted negatively in November as the U.S. Food and Drug Administration requested more testing on the foam used in recalled ventilators and respiratory devices, with the revised estimate suggesting up to 4 million units may require a recall.
- Flutter Entertainment within the Consumer Cyclical - Developed Markets cluster, continued to be impacted by the selloff of US competitors, namely DraftKings, despite retaining market share and the positive indication of a number of new US states approving sports betting in 2022. Flutter also reported their 3Q21 results which included a one off regulatory impact in Netherlands and a small downgrade of their FY21 earnings guidance.

Net performance (%)

	Fund	Benchmark	Difference
1 month	1.1	3.4	-2.3
3 month	-0.2	1.4	-1.6
Year to date	14.5	24.0	-9.5
1 year	14.6	23.9	-9.4
3 year p.a.	11.7	17.1	-5.4
5 year p.a.	11.7	14.9	-3.2
Inception p.a.	11.2	12.2	-1.0

Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes. All p.a. returns are annualised. The inception date of the Antipodes Global Fund – Long (Class P) is 1 August 2015. In order to show performance since the fund's inception, the performance for the period 1 July 2015 to 31 July 2015 is derived from Antipodes Global Fund – Long (Class I) and is adjusted to reflect the fees of Class P.

Performance & risk summary¹

Average net exposure	88.8%
Upside capture ratio	93
Downside capture ratio	80
Portfolio standard deviation	10.7%
Benchmark standard deviation	10.6%
Sharpe ratio	1.07

¹ All metrics are based on gross of fee returns in AUD terms. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility

Performance contribution² (%)

	1 month
Long	1.1%
Currency	0.1%

² Based on gross returns in AUD

Top & bottom sector contribution^{2,4} (%)



⁵ Antipodes classification

Fund facts

Characteristics

Investment manager	Antipodes Partners
Inception date	1 July 2015
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.20% p.a.
Performance fee	15% of net return in excess of benchmark
Buy/Sell spread	±0.30%
Minimum investment	AUD \$25,000
Distribution	Annual, 30 June


Asset value

Fund AUM	\$1,110m
Strategy AUM	\$3,269m
Unit redemption price	1.2047

Asset allocation³

	Equities - Long	Other - Long
Weight (%)	93.3	-
Count	60	-
Avg. weight (%)	1.6	-
Top 10 (%)	30.0	-
Top 30 (%)	67.7	-


³Call (put) options represented as the current option value (delta adjusted exposure)

Sector exposure^{3,4} (%)

⁴ Antipodes classification

Top 10 equity longs³ (%)

Name	Country	Weight
Microsoft	United States	3.6
Frontier Communications Parent	United States	3.4
Meta Platforms	United States	3.4
Tencent	China/HK	3.1
Siemens	Germany	3.1
Taiwan Semiconductor	Taiwan	3.0
Sanofi	France	2.9
Tesco	United Kingdom	2.6
Amazon.com	United States	2.5
Coterra Energy	United States	2.3

Currency exposure^{3,5} (%)

⁵ Where possible, regions, countries and currencies classified on a look through basis

Regional exposure^{3,4,5} (%)

Region	Long
North America	44.0
Western Europe	24.8
- Eurozone	19.1
- United Kingdom	4.1
- Rest Western Europe	1.6
Developing Asia/EM	12.8
- China/Hong Kong	10.9
- India	1.9
Developed Asia	10.4
- Korea/Taiwan	5.7
- Japan	4.7
Australia	1.3
Total Equities	93.3
Cash	6.7
Totals	100.0

Market cap exposure³ (%)

Band	Weight
Mega (>\$100b)	45.7
Large (>\$25b <\$100b)	24.1
Medium (>\$5b <\$25b)	21.8
Small (<\$5b)	1.7

Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

Fund Ratings



Fund features

- Objective to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- In the absence of finding individual securities that meet minimum risk-return criteria, cash may be held to maximum 25%
- Flexibility to hedge for risk management purposes:
 - Currency exposure of the underlying stock position (net short currency position not permitted)
 - Equity market exposure via exchange traded derivatives (limited to 10% of NAV)
 - Leverage not permitted

Further information

- ☎ 1300 010 311
- ✉ invest@antipodespartners.com

Australia Head Office

Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Australia

UK Office

Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK

Disclaimer

This communication is prepared by Antipodes Partners Limited ('Antipodes') ABN 29 602 042 035 AFSL 481580 as the investment manager of the Antipodes Global Fund – Long (ARSN 118 075 764) ('the Fund'). Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 ('PFSL') is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') ABN 22 100 325 184. The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund is available at www.antipodespartners.com. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value. Unless otherwise specified, all amounts are in Australian Dollars (AUD).

Whilst Antipodes, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned Antipodes Global Fund – Long - November 2020) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <https://www.zenithpartners.com.au/our-solutions/investment-research/fund-research-regulatory-guidelines/>.

The Lonsec Ratings (assigned March 2021) presented in this document are published by Lonsec Research presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <https://www.lonsec.com.au/fund-manager/investment-product-ratings>.

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or 'classservice' have been prepared by Morningstar Australasia Pty Ltd (ABN:95090665544, AFSL:240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Refer to Morningstar Financial Services Guide (FSG) for more information at <https://cdn.morningstar.com.au/mca/s/fsg.pdf>. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement (Australian products) or Investment Statement (New Zealand products) before making any decision to invest. Morningstar publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance is for illustrative purposes only and is not indicative of future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN004523782 ("ASXO").

Antipodes Global Fund – Long (class P) received a Morningstar Analyst Rating™ of 'Bronze' on 3 May 2021.